Clinical Trials Sponsored by Novartis Pharma B.V.

Total 227 results

Borstkanker Onderzoek Groep
Novartis Pharma B.V.; BOOG Study Center

Recruiting

SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast) (SEQUEL-Breast)

Neoplasm, Breast | Congenital, Familial and Genetic Disorders

Netherlands
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder

Overactive Bladder | Pharmacokinetics of Mirabegron | Neurogenic Detrusor Overactivity

Belgium, Denmark, Norway, Poland, Serbia
Astellas Pharma Europe B.V.

Completed

A Study of MA-0217 (ASP1128) in Healthy Adult Subjects and Healthy Elderly Subjects

Healthy Volunteers

United States
Astellas Pharma Europe B.V.

Completed

A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis (SERENITY)

Interstitial Cystitis | Bladder Pain Syndrome

Spain, Russian Federation, Belgium, Czechia, Germany, Hungary, Latvia, Netherlands, Poland, United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease

Healthy Subjects | Type 2 Diabetes Mellitus (T2DM) | Chronic Kidney Disease (CKD) | Pharmacokinetics of ASP8232 | Pharmacodynamics of ASP8232

Bulgaria, Moldova, Republic of, Romania
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME) (VIDI)

Diabetes Mellitus | Diabetic Macular Edema

United States
Astellas Pharma Europe B.V.

Completed

A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder (SYNERGY II)

Overactive Bladder | Urgency Incontinence | Urinary Bladder Overactive | Urinary Bladder Diseases\Urologic Diseases

Belgium, Russian Federation, Korea, Republic of, United States, Germany, Spain, Australia, Bulgaria, Canada, Czechia, Denmark, Estonia, Finland, Hungary, Italy, Latvia, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, ... and more
Astellas Pharma Europe B.V.

Completed

Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms (Neptune II)

Lower Urinary Tract Symptoms | Benign Prostatic Hyperplasia

Belgium, Italy, France, Austria, United Kingdom, Netherlands, Poland, Slovakia, Belarus, Germany, Czechia
Astellas Pharma Europe B.V.

Completed

A Phase 1 Study to Investigate the Mechanism of Action of Ipragliflozin

Type 2 Diabetes Mellitus

Germany
Astellas Pharma Europe B.V.

Completed

Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract Symptoms (Neptune)

Lower Urinary Tract Symptoms | Benign Prostatic Hyperplasia

Belgium, Italy, France, Austria, United Kingdom, Netherlands, Hungary, Russian Federation, Poland, Slovakia, Czech Republic, Belarus, Germany
Astellas Pharma Europe B.V.

Completed

Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder (Blossom)

Urinary Bladder, Overactive

Belgium, Czech Republic, Germany, Spain, Sweden, United Kingdom
Astellas Pharma Europe B.V.

Completed

An Observational Study Looking at How Well the Drug Eligard Works and How Well it is Tolerated by the Body of Patients With Advanced Prostate Carcinoma in the Russian Federation

Advanced Prostate Carcinoma

Russian Federation
Astellas Pharma Europe B.V.

Completed

A Combined Single and Multiple Ascending Dose Study of ASP6858 in Healthy Subjects

Healthy Volunteers

United Kingdom
Astellas Pharma International B.V.

Terminated

Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic Leukaemia (CLL) Or Indolent Non Hodgkin's Lymphoma (iNHL) (NADIR)

Chronic Lymphocytic Leukaemia (CLL) | Indolent Non Hodgkin's Lymphoma (iNHL)

Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, United Arab Emirates
Astellas Pharma Europe B.V.

Completed

A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement Surgery (ONYX-3)

Venous Thromboembolism | Arthroplasty, Replacement, Hip

Denmark, Spain, United States, Austria, Colombia, Russian Federation, India, Italy, United Kingdom, Germany, Hungary, Estonia, Romania, South Africa, Israel, Poland, Sweden, Canada, Australia, Lithuania, Ukraine, Latvia, Finland, Brazil, Slovak... and more
Astellas Pharma Europe B.V.

Completed

A Study to Investigate the Effect of Oral Doses of Pilocarpine on Salivary Secretion and Static Pupillometry in Healthy Subjects

Healthy Subjects

United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Safety, Tolerability and Effects of Single and Multiple Ascending Doses of ASP1707 in Healthy Male and Pre-menopausal Female Subjects, Including a Comparison of the Effects Under Fasted and Fed Conditions in Healthy Young Male Subjects

Pharmacokinetics of ASP1707 | Pharmacodynamics of ASP1707

France
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

A Study of Solifenacin With Bladder Training Versus Solifenacin Alone in Patients With Overactive Bladder (SOLAR) (SOLAR)

Overactive Bladder | Urinary Incontinence | Urge Incontinence

France, Belgium, Spain, Turkey, Australia, Russian Federation, Hungary, Italy, Netherlands, Poland, Czech Republic
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate Whether Verapamil Has an Effect on the Uptake and Elimination of Solifenacin and Tamsulosin When Administered in a Combination Tablet

Healthy Subjects | Drug-Drug Interaction (DDI)

France
Astellas Pharma Europe B.V.

Completed

A Study to Compare the Amount of Drug in the Blood After a Single Tablet EC905 Containing Solifenacin and Tamsulosin is Taken by Healthy Males Compared to Separate Tablets of Solifenacin and Tamsulosin

Healthy Subjects | Pharmacokinetics | EC905

United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Pharmacokinetics, Metabolism and Excretion Routes of ASP3652 in Man, After Administration of 14C Radio Labeled ASP3652

Healthy Subjects | Pharmacokinetics of ASP3652

United Kingdom
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)

Overactive Bladder

Poland, United Kingdom, Germany, Spain, Netherlands, Belgium, Czech Republic, Italy, Norway, Hungary, Sweden, Denmark, Greece, France, Russian Federation
Astellas Pharma Europe B.V.

Completed

A Study to Compare the Actions in the Body of Healthy Subjects of Three Modified Release Formulations of YM178 Under Fasted and Fed Conditions With One Immediate Release Formulation of YM178 Under Fasted Conditions

Healthy Subjects | Pharmacokinetics of YM178

Netherlands
Astellas Pharma Europe B.V.

Completed

A Study to Find Out How YM150 is Absorbed Into and Eliminated From the Body in Healthy Male Subjects

Healthy Male Subjects | Pharmacokinetics

Netherlands
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

Factor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins After Scheduled Hip Replacement (ONYX-2)

Thromboembolism

Italy, Spain, Sweden, Austria, Denmark, Russian Federation, Poland, Bosnia and Herzegovina, Serbia, Norway, Latvia, Finland, Lithuania, Czech Republic, Germany, Slovakia, Greece
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Safety, Tolerability and Effects of Single Ascending Doses of ASP3652 in Healthy Subjects

Healthy Subjects | Pharmacokinetics | Pharmacodynamics | Safety

Netherlands
Astellas Pharma Europe B.V.

Completed

Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity (Crocodile)

Neurogenic Detrusor Overactivity

Belgium, Croatia, Turkey, Australia, Denmark, Israel, Jordan, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico, Norway, Philippines, Poland, Romania, Serbia, Slovakia, Taiwan
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)

Overactive Bladder | Neurogenic Detrusor Overactivity

Denmark, Poland
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Analgesic Efficacy of ASP7962 in Patients With Pain Due to Osteoarthritis of the Knee (OAK)

Osteoarthritis of the Knee | Chronic Lower Back Pain

Belgium, Czechia, Germany, Hungary, Spain, United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Effectiveness and Safety of Different Doses of ASP1707 Compared to Placebo for Endometriosis Associated Pelvic Pain

Endometriosis

Belgium, Bulgaria, Germany, Hungary, Japan, Poland, Romania, Ukraine, United Kingdom
Astellas Pharma Europe B.V.

Completed

A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)

Pediatric | Neurogenic Detrusor Overactivity

United States, Belgium, Korea, Republic of, Philippines, Poland, United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease (ALBUM)

Type 2 Diabetes | Chronic Kidney Disease

Spain, Czechia, Denmark, Germany, Hungary, Italy, Netherlands, Poland, United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Efficacy and Safety of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin (IMPRESSION)

Type 2 Diabetes Mellitus

Russian Federation
Astellas Pharma Europe B.V.

Completed

This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder (SYNERGY)

Overactive Bladder | Urgency Incontinence | Urinary Bladder Overactive | Urinary Bladder Diseases\Urologic Diseases

United States, Argentina, Australia, Belgium, Bulgaria, Canada, China, Colombia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, Italy, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico, Netherlands and more
Astellas Pharma Europe B.V.

Completed

A Study Into Pain Relief Given by ASP8477 for Peripheral Neuropathic Pain (Either Post-herpetic Neuralgia or Painful Diabetic Peripheral Neuropathy) and Its Safety (MOBILE)

Neuropathic Pain | Post-Herpetic Neuralgia (PHN) | Painful Diabetic Peripheral Neuropathy (PDPN)

Czechia, Germany, Poland, United Kingdom
Astellas Pharma Europe B.V.

Terminated

A Study To Assess The Efficacy And Safety Of Bismuth Tripotassium Dicitrate (De-Nol) In Combination With Pantoprazole And Pantoprazole Monotherapy In Treatment Of Subjects With Nonsteroidal Anti-Inflammatory Drugs (NSAID)-Induced Gastropathy (BiGARD)

NSAID-induced Gastropathy

Russian Federation
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP6294 Administered Intravenously or Subcutaneously in Healthy Young Male and Female Subjects

Healthy Subjects | Pharmacokinetics of ASP6294

United Kingdom
Astellas Pharma Europe B.V.

Completed

First-in-human: Single Ascending Dose, Food Effect, Drug-drug Interaction, Multiple Ascending Dose, Proof of Pharmacology

Healthy Volunteers

United Kingdom, Germany
Astellas Pharma Europe B.V.

Terminated

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP2205 in Healthy Young Males and Females and Elderly Females and to Evaluate the Effect of Food on the Pharmacokinetics of a Single Dose of of ASP2205

Healthy Subjects | Pharmacokinetics of ASP2205

United Kingdom
Astellas Pharma Europe B.V.

Completed

EC905 Pharmacokinetic Profile Study

Healthy | Lower Urinary Tract Symptoms | Benign Prostatic Hyperplasia | Phase 1

Netherlands
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Multiple Ascending Doses of ASP7962 in Healthy Subjects (MAD)

Healthy Volunteers | Pharmacokinetics of ASP7962

United Kingdom
Astellas Pharma Europe B.V.

Terminated

To Determine the Feasibility of a Fidaxomicin Study in Neonates and to Assess C. Difficile (Clostridium Difficile) Involvement in the Pathogenesis (DAISY)

Clostridium Difficile

France, Germany, Netherlands, Spain
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Effects of Single Ascending Doses (SAD) of ASP8477, the Effect That Food Has on the Drug, and the Interaction Between ASP8477 and Omeprazole in Healthy Postmenopausal Females and Healthy Young Vasectomized Males

Pharmacokinetics of ASP8477 | Pharmacodynamics of ASP8477

France, Belgium
Astellas Pharma Europe B.V.

Completed

Study to Evaluate the Effect of Solifenacin and Mirabegron on the Digoxin Concentrations in Blood in Healthy Subjects

Healthy Subjects | Pharmacokinetics | Drug-Drug Interaction (DDI)

Germany
Astellas Pharma Europe B.V.

Completed

A Clinical Trial to Investigate Safety and Tolerability of ASP7962 in Healthy Humans

Tolerability | Safety | Pharmacokinetics of ASP7962

United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Interaction Between ASP1707 and Itraconazole in Healthy Female Subjects

Healthy Subjects | Pharmacokinetics | DDI (Drug-Drug Interaction)

Germany
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate How Tamsulosin (at 1 Dose) and Solifenacin (at 2 Different Doses) Are Taken up From the Intestine, Distributed Through the Body and Eliminated From the Body When Administered in Combination as a Single Tablet (Called EC905)

Healthy Subjects | Pharmacokinetics | EC905 | Multiple Dose

United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate Whether Food Has an Effect on the Uptake of Solifenacin and Tamsulosin When Administered in a Combination Tablet

Healthy Subjects | Pharmacokinetics | EC905

United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Effects of Single Ascending Doses of ASP1707 in Healthy Young Japanese Male Subjects

Healthy Subjects

United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Effect of ASP1707 on the Bodies of Healthy Male Subjects After a Single Dose of Radioactive ASP1707

Pharmacokinetics of ASP1707

United Kingdom

Clinical Trials Sponsored by Novartis Pharma B.V.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Romania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations